Genmab
GMAB
233 hedge funds and large institutions have $1.67B invested in Genmab in 2023 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 96 increasing their positions, 56 reducing their positions, and 21 closing their positions.
95% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 21
71% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 56
9% more funds holding
Funds holding: 213 → 233 (+20)
8.68% more ownership
Funds ownership: 63.15% → 71.83% (+8.7%)
6% more capital invested
Capital invested by funds: $1.59B → $1.67B (+$89.5M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
22% less call options, than puts
Call options by funds: $1.61M | Put options by funds: $2.07M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HL
Harding Loevner
Bridgewater,
New Jersey
|
+$116M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$50.6M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$17.4M |
| 4 |
Renaissance Technologies
New York
|
+$12.8M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$9.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$14.8M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$13.2M |
| 3 |
Jane Street
New York
|
-$6.57M |
| 4 |
Two Sigma Investments
New York
|
-$5.13M |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$4.67M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
251
Simplex Trading
Chicago,
Illinois
| – | -$4.61K | -121 | Closed |
|
|
IPW
252
Impact Partnership Wealth
Marietta,
Georgia
| – | -$1.75K | -46 | Closed |
|
|
FBC
253
Fairfield, Bush & Co
Darien,
Connecticut
| – | -$1.14K | -30 | Closed |
|
|
M
254
MOTCO
San Antonio,
Texas
| – | -$494 | -13 | Closed |
|
GMAB Hedge Fund Activity: Q3 2023 in Review
233 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q3 2023, worth a combined $1.67B — up 5.6% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new GMAB positions and 21 closed out — a net gain of 20 holders — while 96 added to existing stakes and 56 trimmed.
The largest buyer was Harding Loevner, adding an estimated $116M. The largest seller was BlackRock, cutting an estimated $14.8M.
- 233 institutional investors held Genmab (GMAB) as of Q3 2023, up from 213 in Q2 2023.
- Funds reported $1.67B of Genmab stock for Q3 2023, up 5.6% quarter-over-quarter.
- 41 funds opened new Genmab positions in Q3 2023 and 21 closed out, a net change of +20 holders.
- The largest Genmab buyer in Q3 2023 was Harding Loevner, an estimated $116M added.
- The largest Genmab seller in Q3 2023 was BlackRock, an estimated $14.8M sold.
Based on aggregated 13F filings for Q3 2023.